<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808080</url>
  </required_header>
  <id_info>
    <org_study_id>070768</org_study_id>
    <nct_id>NCT00808080</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>AMLCTL</acronym>
  <official_title>A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas A. Lane, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this protocol is to investigate a novel form of immune therapy for patients with
      acute myelogenous leukemia (AML) who are in remission (CR) but who are at high risk for
      relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Aim: To conduct a Phase 1/2 clinical trial of autologous CTL-mediated immunotherapy
      in a homogeneous group of patients with AML who have recently received an autologous
      hematopoietic stem cell transplant. Specifically:

      Phase 1: To determine the MTD of autologous AML-reactive cultured CTL in patients with AML
      who have recently received an AHSCT.

      Phase 2: To determine 1 year progression-free survival of the study group vs institutional
      historical control group composed of a sequential series of recent patients who have received
      an AHSCT for AML.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of accrual
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Dose Cohorts for Safety Monitoring. Each Cohort is Assessed for DLT for One Month After Autologous Cultured CTL Infusion Prior to Enrolling the Next Cohort.</measure>
    <time_frame>2.5 years estimated</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>If Phase I Has Successfully Shown the Target Dose to be Below the MTD Continue Enrolling Until 38 Patients Have Received the Target Dose. Patients Will be Monitored for Safety and Efficacy.</measure>
    <time_frame>2.5 years estimated</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Biologic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML_CTL cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMLCTL</intervention_name>
    <description>Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)</description>
    <arm_group_label>Biologic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Initial Eligibility Screen):

          -  Diagnosis of AML, not M3

          -  At least 10% of circulating leukocytes are AML blast cells

          -  Age 18 through 75

          -  Sex male or female

          -  Patient is considered a potential candidate for AHSCT

        Exclusion criteria (Initial Eligibility Screen):

          -  Participation in another immunotherapy trial within 30 days

          -  Presence of active malignancy other than AML

          -  History of autoimmune disease requiring systemic treatment

          -  ECOG performance status of 3 or 4

          -  Major organ system dysfunction

          -  Recent (30 days) or current use of steroids other than topical skin preparations

          -  History of allogeneic transplant

          -  Patients who, for any reason are not deemed candidates for AHSCT

        Eligibility for autologous CTL Infusion:

        Inclusion Criteria:

          -  Patient has CTL that are in sufficient number and are suitable for infusion

          -  Patient is stable, afebrile, engrafted, ECOG status 0-2, in CR and received AHSCT 45 -
             60 days earlier.

        Exclusion or delay criteria:

          -  Temperature &gt; 38 C and/or known to be infected

          -  Absence of engraftment ANC &gt; 500 and Plt &gt; 20,000 unsupported

          -  Life expectancy less than 6 weeks

          -  Autoimmune disease requiring systemic treatment.

          -  ECOG performance status of 3 or 4

          -  Major organ system dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Lane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>LA Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <results_first_submitted>November 30, 2015</results_first_submitted>
  <results_first_submitted_qc>January 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Thomas A. Lane, MD</investigator_full_name>
    <investigator_title>Professor of Pathology</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Biologic</title>
          <description>AML_CTL cells
AMLCTL: Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
6 patients were enrolled, however none of the 6 patients became eligible to receive the AML CTL Infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients Became Ineligible for infusion</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Biologic</title>
          <description>AML_CTL cells
AMLCTL: Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Circulating Blasts In Peripheral Blood</title>
          <units>percentage of peripheral blood</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" lower_limit="26" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Blast Cells in Bone Marrow</title>
          <units>percentage of bone marrow</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" lower_limit="45" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WBC at Baseline</title>
          <units>1000 cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.4" lower_limit="4" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ANC at Baseline</title>
          <units>1000 cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2460.7" lower_limit="480" upper_limit="7398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6 Dose Cohorts for Safety Monitoring. Each Cohort is Assessed for DLT for One Month After Autologous Cultured CTL Infusion Prior to Enrolling the Next Cohort.</title>
        <time_frame>2.5 years estimated</time_frame>
        <population>Not Applicable as none of the enrolled patients became eligible for infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic</title>
            <description>AML_CTL cells
AMLCTL: Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
6 patients were enrolled, however none of the 6 patients became eligible to receive the AML CTL Infusion</description>
          </group>
        </group_list>
        <measure>
          <title>6 Dose Cohorts for Safety Monitoring. Each Cohort is Assessed for DLT for One Month After Autologous Cultured CTL Infusion Prior to Enrolling the Next Cohort.</title>
          <population>Not Applicable as none of the enrolled patients became eligible for infusion</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>If Phase I Has Successfully Shown the Target Dose to be Below the MTD Continue Enrolling Until 38 Patients Have Received the Target Dose. Patients Will be Monitored for Safety and Efficacy.</title>
        <time_frame>2.5 years estimated</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse events or serious adverse events occurred related to study treatment as no patients have received their AML CTL infusion.</desc>
      <group_list>
        <group group_id="E1">
          <title>Biologic</title>
          <description>AML_CTL cells
AMLCTL: Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
6 patients were enrolled, however none of the 6 patients became eligible to receive the AML CTL Infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Accrual trial was insufficient. No patient became eligible for CTL infusion. Cell culture information gleaned from a comparison of different culture methods will greatly facilitate future studies of autologous CTL-directed immunotherapy for AML.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Thomas Lane, Stem Cell Lab Director</name_or_title>
      <organization>UC San Diego Moores Cancer Center</organization>
      <phone>858-822-5364</phone>
      <email>jreiner@Ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

